Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects

Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Mosc...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Human vaccines & immunotherapeutics Ročník 18; číslo 5; s. 2060018
Hlavní autori:	Borgonovo, Fabio, Stangalini, Carlo Alberto, Tinelli, Carmine, Mariani, Chiara, Mileto, Davide, Cossu, Maria Vittoria, Abbati, Laura, Bilardo, Lara, Gagliardi, Gloria, Cutrera, Miriam, Pellicciotta, Martina, Armiento, Luciana, Dedivitiis, Gianfranco, Capetti, Amedeo F., Rizzardini, Giuliano
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Taylor & Francis 30.11.2022 Taylor & Francis Group
Predmet:	Aged Antibodies, Viral antibody BNT162 Vaccine Brief Report Coronavirus – Short Report covid-19 COVID-19 - prevention & control decline Humans igg Immunoglobulin G kinetics SARS-CoV-2 spike Vaccination vaccine COVID-19 SARS-CoV-2 vaccine antibody IgG decline kinetics spike
ISSN:	2164-5515, 2164-554X, 2164-554X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!